Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Biol Ther. 2014 Jun 1;15(6):665-74. doi: 10.4161/cbt.28555. Epub 2014 Mar 20.

Melanoma immunotherapy.

Author information

1
University of California San Francisco; San Francisco, CA USA; Department of Medical Sciences; Section of Dermatology; University of Turin; Turin, Italy.
2
University of California San Francisco; San Francisco, CA USA; The Rudolfstiftung Hospital; Vienna, Austria.
3
University of California San Francisco; San Francisco, CA USA.
4
Department of Medical Sciences; Section of Dermatology; University of Turin; Turin, Italy.

Abstract

Immunotherapy is a cornerstone in the treatment of melanoma, and is intended to modulate the host immunity against the tumor. Immunotherapy can be used in an adjuvant setting, after complete surgical excision in patients with a high risk of disease relapse and as a treatment in advanced (unresectable or metastatic) stages. Development of novel therapeutic approaches and the optimization of existing therapies hold a great promise in the field of melanoma therapy research. Different clinical trials are ongoing, and immunotherapy is showing the ability to confirm durable clinical benefits in selected groups of melanoma patients. The aim of this review is to summarize different types of immunotherapy agents, as well as to discuss different strategies, complementary regimens, and possible biomarkers of response to the treatment.

KEYWORDS:

CTLA-4; PD-1; anti-PD-1; immunoprofiling; interferons; interleukins; ipilimumab

PMID:
24651672
PMCID:
PMC4049781
DOI:
10.4161/cbt.28555
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center